American clinical stage biotechnology company at Kingston in Rhode Island, founded in 2016 on the campus of the University of Rhode Island by neuroscientists and immunologists working on the immune drivers of neurodegeneration. Develops antibody and small molecule therapies aimed at the inflammatory processes believed to drive Alzheimer's disease and related conditions, with its lead programme MITI 101 and further discovery work on neuroimmune targets, and runs its own laboratories in partnership with the university's George and Anne Ryan Institute for Neuroscience.
Aucun commentaire disponible.
Laissez votre note & commentaire